NASDAQ: ACRV - Acrivon Therapeutics, Inc.

الربحية لمدة ستة أشهر: -68%
عائد الأرباح: 0.00%
قطاع: Healthcare

جدول الترويج Acrivon Therapeutics, Inc.


عن الشركة Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

مزيد من التفاصيل
Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.

IPO date 2022-11-15
ISIN US0048901096
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.acrivon.com
Цена ао 2.61
تغير السعر يوميا: -11.11% (2.52)
تغير السعر في الأسبوع: -58.21% (5.36)
تغير السعر شهريا: -57.82% (5.31)
تغير السعر خلال 3 أشهر: -62.16% (5.92)
تغير السعر على مدى ستة أشهر: -68% (7)
تغير السعر سنويا: -68.67% (7.15)
تغير الأسعار منذ بداية العام: -58.6% (5.41)

الاستهانة

اسم معنى درجة
P/S 0 0
P/BV 0.9109 9
P/E 0 0
EV/EBITDA -1.18 0
المجموع: 3.63

كفاءة

اسم معنى درجة
ROA, % -43.68 0
ROE, % -49.83 0
المجموع: 0

توزيعات الأرباح

اسم معنى درجة
Div yield, % 0 0
DSI 0 0
المجموع: 0

واجب

اسم معنى درجة
Debt/EBITDA -0.0696 10
المجموع: 9.2

دافع النمو

اسم معنى درجة
الربحية Revenue, % 0 0
الربحية Ebitda, % 1770.38 10
الربحية EPS, % 564.2 10
المجموع: 8

المؤسسات مقدار يشارك, %
RA Capital Management, L.P. 4810508 21.25
Perceptive Advisors LLC 3007858 13.29
Sands Capital Ventures, LLC 1652605 7.3
Citadel Advisors Llc 1649659 7.29
Wellington Management Group, LLP 888130 3.92
Marshall Wace LLP 597469 2.64
Blackrock Inc. 565832 2.5
Vanguard Group Inc 475977 2.1
NEA Management Company, LLC 430252 1.9
Federated Hermes, Inc. 226375 1

ETFيشارك, %الربحية لهذا العام, %توزيعات الأرباح, %
Range Cancer Therapeutics ETF 2.03779 47.24 0.11955
iShares Micro-Cap ETF 0.02284 17.09 1.54048
Avantis U.S Small Cap Equity ETF 0.00853 27.77 1.68271
Schwab U.S. Small-Cap ETF 0.00415 17.47 1.51433
ProShares UltraPro Russell2000 0.0019 89.82 1.47873
ProShares Hedge Replication ETF 0.00053 5.92 1.47892
Schwab U.S. Broad Market ETF 0.00053 24.86 1.43354
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 3000 ETF 0 31.87 1.43817
0.2331.021.35



مشرف مسمى وظيفي قسط سنة الميلاد
Dr. Peter Blume-Jensen M.D., Ph.D. Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer 977.7k 1963 (62 سنة)
Ms. Kristina Masson M.B.A., Ph.D. Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director 739.78k 1981 (44 سنة)
Mr. Rasmus Holm-Jorgensen Chief Financial Officer 1M 1972 (53 سنة)
Dr. Eric J. Devroe Ph.D. Chief Operating Officer 614.78k 1979 (46 سنين)
Ms. Katharine Peterson CPA Vice President of Finance & Accounting N/A
Dr. Adam D. Levy M.B.A., Ph.D. Senior VP and Head of Investor Relations & Corporate Affairs N/A
Mr. Bruce Close Vice President of Quality & Compliance N/A
Ms. Mary-Alice Miller J.D. Chief Legal Officer 587.11k 1974 (51 سنة)
Ms. Parvin Miah VP & Head of Human Resources N/A
Dr. Erick Gamelin M.D., Ph.D. Chief Development Officer 480.72k 1958 (67 سنين)

عنوان: United States, Watertown. MA, 480 Arsenal Way - مفتوحة في خرائط جوجل, فتح خرائط ياندكس
موقع إلكتروني: https://www.acrivon.com